A Dialysis Membrane-Integrated Microfluidic Device for Controlled Drug Retention and Nutrient Supply

Area of Science:

• Biomedical Engineering
• Pharmacology
• In Vitro Toxicology

Background:

• Traditional preclinical drug evaluation methods (animal models, static cell cultures) have significant limitations, including poor physiological relevance and ethical concerns.
• Microphysiological systems (MPSs) offer improved human-relevance through perfusion cell culture but standard protocols lack continuous pharmacokinetic simulation due to discrete medium changes.
• Abrupt changes in drug concentration in current MPS hinder accurate in vivo pharmacokinetic mimicry.

Purpose of the Study:

• To develop a microfluidic device that overcomes the limitations of discrete medium changes in standard MPS.
• To establish a platform that maintains continuous drug concentrations, better reflecting in vivo pharmacokinetics.
• To enhance the accuracy and human-relevance of in vitro drug efficacy and toxicity assessments.

Main Methods:

• Development of a Dialysis Membrane-integrated Microfluidic Device (DMiMD) utilizing a dialysis membrane for selective medium exchange.
• Characterization of the membrane's molecular weight cut-off (MWCO) to ensure retention of high-molecular-weight drugs and passage of low-molecular-weight nutrients (e.g., glucose).
• Validation of nutrient supply and molecular selectivity using cell cultures, followed by evaluation of anticancer drug efficacy under continuous drug concentration dynamics.

Main Results:

• The DMiMD successfully maintained continuous drug concentrations by enabling selective medium exchange via a dialysis membrane.
• The membrane's MWCO was confirmed to retain large molecules while allowing essential nutrient passage, ensuring cell viability.
• Anticancer drug efficacy was accurately assessed under dynamic, in vivo-like drug exposure conditions, validating the DMiMD's performance.

Conclusions:

• The developed DMiMD provides a robust in vitro platform for more accurate drug efficacy and toxicity evaluations.
• This device effectively bridges the gap between conventional static assays and the physiological complexity of the human body.
• The DMiMD offers a significant advancement for preclinical drug development by mimicking in vivo drug exposure dynamics.